StockNews.AI
ICCM
StockNews.AI
151 days

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

1. IceCure Medical will release 2024 financial results on March 27, 2025. 2. A conference call will discuss financial and operational updates. 3. The ProSense system targets multiple cancer types effectively. 4. Results may influence investor sentiment and stock performance.

Earnings
0%Current Return
VS
-0.27%S&P 500
$1.2503/21 08:49 AM EDTEvent Start
$1.2503/24 09:12 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results and positive operational developments may drive investor interest, similar to past earnings reports that positively impacted health tech stocks.

How important is it?

Investors typically react strongly to earnings announcements, particularly for innovative health tech firms like ICCM.

Why Short Term?

The results announcement and conference call could prompt immediate market reactions, typical for earnings disclosures.

Related Companies

GNEMDGL
, /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2024 before the Nasdaq Stock Market opens on Thursday, March 27, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info: Thursday, March 27, 2025, at 10:00 am EDTUS: 1-888-407-2553Israel/International: +972-3-918-0696A live webcast will be available at:  https://Veidan.activetrail.biz/IcecureQ4-2024.A recording of the webcast will be available at: ir.icecure-medical.com/. About IceCure Medical IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. IR Contact:  Email: [email protected] Michael Polyviou Phone: 732-232-6914 Todd Kehrli Phone: 310-625-4462 Logo - https://mma.prnewswire.com/media/2319310/4496307/IceCure_Medical_Logo.jpg SOURCE IceCure Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News